SPRY
ARS Pharmaceuticals, Inc
NASDAQ: SPRY · HEALTHCARE · BIOTECHNOLOGY
$8.26
+5.36% today
Updated 2026-04-30
Market cap
$788.42M
P/E ratio
—
P/S ratio
9.36x
EPS (TTM)
$-1.74
Dividend yield
—
52W range
$7 – $19
Volume
1.5M
ARS Pharmaceuticals, Inc (SPRY) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | $27.55M | $15.65M | $26.41M | $61.45M | $281.44M | $233.19M | $351.15M |
| Cash & equivalents | $20.16M | $9.98M | $24.52M | $60.06M | $210.52M | $70.97M | $50.82M |
| Current assets | $20.78M | $10.53M | $26.38M | $60.73M | $277.70M | $231.56M | $334.30M |
| Total liabilities | $9.35M | $21.25M | $40.46M | $92.72M | $8.55M | $2.43M | $94.36M |
| Current liabilities | $5.14M | $17.93M | $8.21M | $8.19M | $5.44M | $2.39M | $23.44M |
| Long-term debt | — | — | $7.46M | $4.93M | — | — | — |
| Shareholder equity | $18.20M | $-5.60M | $-14.05M | $-31.27M | $272.89M | $230.76M | $256.80M |
| Retained earnings | $-39.82M | $-63.79M | $-22.01M | $-42.26M | $-76.94M | $-131.30M | $-123.31M |
| Accounts receivable | — | — | $384000.00 | $1000.00 | $1.01M | $795000.00 | $9.16M |
| Inventory | — | — | $-2.61M | $-6.78M | $-1.01M | $0.00 | $5.21M |
| Goodwill | — | — | — | — | — | — | — |